Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03430544 · ClinicalTrials.gov registry record · Phase 2
Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder
A Phase 2 study, sponsored by Anna Rose Childress, Ph.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03430544 is a Phase 2 study that was terminated before completion, run by Anna Rose Childress, Ph.D.. The registered enrollment target is 14 participants.
The verdict
NCT03430544, a Phase 2 study, was terminated before completion, sponsored by Anna Rose Childress, Ph.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a phase II, randomized, single-blind, placebo-controlled study to examine whether cariprazine (1.5 or 3 mg/d) 1) alters brain and/or behavioral responses to probes of reward and inhibition and 2) decreases cocaine use in individuals with cocaine use disorder. Subjects will be tested as inpatients during fMRI sessions. After the 2-week inpatient/medication induction phase, study medication will continue for 8 outpatient weeks, during which time cocaine use will be tracked. Subjects will be monitored during a 4-wk followup phase thereafter.
Interventions
- DRUG Placebo oral capsule
- DRUG Cariprazine Oral Capsule [Vraylar]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-04-04 |
| Est. Completion | 2020-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03430544
The ClinicalTrials.gov registry entry for NCT03430544 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anna Rose Childress, Ph.D., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03430544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03430544 about?
NCT03430544 is a clinical study titled "Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder". This is a phase II, randomized, single-blind, placebo-controlled study to examine whether cariprazine (1.5 or 3 mg/d) 1) alters brain and/or behavioral responses to probes of reward and inhibition and 2) decreases cocaine use in individuals with cocaine use disorder. Subjects will be tested as inpat...
What is the current status of trial NCT03430544?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2018-04-04. Estimated completion is 2020-09-04.
What interventions are being tested in trial NCT03430544?
The interventions under investigation include: Placebo oral capsule (DRUG), Cariprazine Oral Capsule [Vraylar] (DRUG).
Who is sponsoring clinical trial NCT03430544?
This trial is sponsored by Anna Rose Childress, Ph.D., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.